(29 days)
Not Found
No
The document describes a hip implant component and its intended use, comparing it to a predicate device. There is no mention of AI or ML technology in the description, intended use, or performance studies.
Yes
The device, "Total hip components," is indicated for individuals undergoing primary and revision surgery to rehabilitate hips damaged by various conditions, which are therapeutic purposes.
No
The device is an orthopedic implant (acetabular components for hip replacement surgery), not a tool for diagnosing medical conditions. It is used to treat existing conditions of the hip.
No
The device description clearly states it is an "Acetabular Component," which is a physical implant used in hip replacement surgery. The summary discusses materials (UHMWPE, zirconia ceramic) and performance testing related to physical properties, not software functionality.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information about a person's health.
- Device Description and Intended Use: The provided text clearly describes a total hip component, specifically an acetabular component (part of the hip socket). Its intended use is for surgical implantation in individuals undergoing hip replacement surgery due to various conditions affecting the hip joint.
- Lack of Diagnostic Testing: There is no mention of this device being used to analyze samples or perform any kind of diagnostic test. It is a physical implant designed to replace a damaged anatomical structure.
Therefore, based on the provided information, this device falls under the category of a surgical implant or prosthetic device, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
Total hip components are indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma, inflammatory joint disease such as rheumatoid arthritis, or noninflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis; avascular necrosis; traumatic arthritis; slipped capital epiphysis; fused hip; fracture of the pelvis and diastrophic variant; old, remote osteomyelitis with an extended drainage-free period; non-union; femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; femoral osteotomy, or Girdlestone resection; fracture dislocation of the hip; and correction of deformity.
Reflection® Cross-linked UHMWPE Acetabular Components are designed for single use only.
Product codes (comma separated list FDA assigned to the subject device)
LPH, JDI
Device Description
The intended use, type of interface, and design features of the Reflection® Cross-linked UHMWPE Acetabular Components are identical to Smith and Nephew, Inc. predicate counterparts cleared for market under K002747.
This Special 510(k) premarket notification is requesting approval for use of Reflection® 10 Mrad . Cross-Linked UHMWPE Acetabular Components with zirconia ceramic femoral heads.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Hip
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Test data indicate that the Reflection® Cross-linked UHMWPE Acetabular Components meet the requirements of draft Guidance Document for Testing Acetabular Cup Prostheses, dated 05-01-95. The subject devices are identical to predicate devices cleared under K002747.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3358 Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis.
(a)
Identification. A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement.(b)
Classification. Class II.
0
Kol3657
DEC 0 5 2001
510(K) SUMMARY
Page 1 of 2
Reflection® Cross-linked UHMWPE Acetabular Components
In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CRF 807, this information serves as a Mour Do Rosety and Effectiveness for the use of the Reflection® Cross-linked UHMWPE Acetabular Components.
Submitter's name: Submitter's address:
Submitter's telephone number: Contact person: Date summary prepared: Trade or proprietary name:
Common or usual name:
Classification name:
Smith & Nephew, Inc. 1450 Brooks Road Memphis, TN 38116 901-399-6487 David Henley November 5, 2001 Reflection® Cross-linked UHMWPE Acetabular Components Polyethylene Acetabular Components
21 CFR 888.3350 Prosthesis, Hip, Semi-Constrained, metal/polymer, Cemented - Class II
21 CFR 888.3358 Prosthesis, Hip, Semi-Constrained, metal/polymer, Uncemented -Class II
Device Product Code and Panel Code:
Orthopedics/87/LPH, JDI
Substantially Equivalent Legally Marketed Devices
- Reflection® Cross-linked UHMWPE Acetabular Components Smith & Nephew, Inc. .
- Zirconia Ceramic Femoral Heads Smith & Nephew, Inc. .
Device Description:
The intended use, type of interface, and design features of the Reflection® Cross-linked UHMWPE Acetabular Components are identical to Smith and Nephew, Inc. predicate counterparts cleared for market under K002747.
- This Special 510(k) premarket notification is requesting approval for use of Reflection® 10 Mrad . Cross-Linked UHMWPE Acetabular Components with zirconia ceramic femoral heads.
Device Intended Use:
Total hip components are indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma, inflammatory joint disease such as rheumatoid arthritis, or noninflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis; avascular necrosis;
CONFIDENTIAL
1
traumatic arthritis; slipped capital epiphysis; fused hip; fracture of the pelvis and diastrophic variant; old, remote osteomyelitis with an extended drainage-free period; non-union; femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; femoral osteotomy, or Girdlestone resection; fracture dislocation of the hip; and correction of deformity.
Reflection® Cross-linked UHMWPE Acetabular Components are designed for single use only.
Technological Characteristics:
The polyethylene devices that are the subject of this Special 510(k) premarket notification are identical to Smith and Nephew, Inc. predicate device counterparts cleared for market under K002747. Thus, the intended use, material, and design features of Reflection® Cross-linked UHMWPE Acetabular Components are identical to devices approved under K002747. There have been no modifications to the manufacturing process for the Cross-Linked UHMWPE material used to manufacture these devices. The safety and effectiveness for Smith and Nephew's Reflection Cross-Linked UHMWPE material in acetabular liner/cup applications, as well as the proposed wear claims, are adequately supported by the substantial equivalence information, materials data, and testing results provided in this Special 510(k) premarket notification.
Performance characteristics:
Test data indicate that the Reflection® Cross-linked UHMWPE Acetabular Components meet the requirements of draft Guidance Document for Testing Acetabular Cup Prostheses, dated 05-01-95. The subject devices are identical to predicate devices cleared under K002747.
Wear claims:
The following marketing claims will be made for the Reflection® Cross-linked UHMWPE Acetabular Components articulating against zirconia ceramic femoral heads:
-
- No detectable wear as measured gravimetrically.
-
- Generation of 84% fewer particles compare to conventional, non-irradiated UHMWPE used against CoCr femoral heads.
-
- Generation of 79% fewer particles compare to conventional, non-irradiated UHMWPE used against zirconia ceramic femoral heads.
-
- Generation of 41% fewer particles compared to Cross-Linked UHMWPE used against CoCr femoral heads.
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird with three stylized wing segments.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
DEC 0 5 2001
Mr. David Henley Senior Clinical/Regulatory Affairs Specialist Smith + Nephew, Inc. Orthopaedics Division 1450 Brooks Rd., Memphis, Tennessee 38116
Re: K013658
Trade Name: Reflection Cross-Linked UHMWPE Acetabular Components Regulation Number: 21 CFR 888.3350 and 888.3358 Regulation Name: Hip joint metal/polymer semi-constrained cemented prosthesis and Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis Regulatory Class: Class II Product Code: LPH and JDI Dated: November 5, 2001 Received: November 6, 2001
Dear Mr. Henley
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 -- Mr. David Henley
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.
Sincerely yours,
b. Mark N. Millman
Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications Statement
K013658
page 1 of 1
Reflection® Cross-linked UHMWPE Acetabular Components
Total hip components are indicated for individuals undergoing primary and revision surgery where other treatments or devices have failed in rehabilitating hips damaged as a result of trauma, inflammatory joint disease such as rheumatoid arthritis, or noninflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis; avascular necrosis; traumatic arthritis; slipped capital epiphysis; fused hip; fracture of the pelvis and diastrophic variant; old, remote osteomyelitis with an extended drainage-free period; non-union; femoral neck fracture and trochanteric fractures of the proximal femur with head involvement that are unmanageable using other techniques; femoral osteotomy, or Girdlestone resection; fracture dislocation of the hip; and correction of deformity.
Mark N Milken
eral. Pestorative
510(k) N"y"